Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

Tanaka, Kazuki; Adams, Brigitte; Aris, Alvaro Madrid; Fujita, Naoya; Ogawa, Masayo; Ortiz, Stephan; Vallee, Marc; Greenbaum, Larry A

Tanaka, Kazuki; Adams, Brigitte; Aris, Alvaro Madrid; Fujita, Naoya; Ogawa, Masayo; Ortiz, Stephan; Vallee, Marc; Greenbaum, Larry A.

Afiliação

Tanaka K; Department of Nephrology, Aichi Children's Health and Medical Center, 7-426, Morioka-cho, Obu City, Aichi prefecture, 474-8710, Japan. kazuki.tanaka0505@gmail.com.
Adams B; Department of Pediatric Nephrology, Children's Hospital Queen Fabiola, Université libre de Bruxelles, Brussels, Belgium.
Aris AM; Children's Nephrology and Renal Transplantation Service, Children's Maternity Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Fujita N; Department of Nephrology, Aichi Children's Health and Medical Center, 7-426, Morioka-cho, Obu City, Aichi prefecture, 474-8710, Japan.
Ogawa M; Alexion Pharmaceuticals Inc, Boston, MA, USA.
Ortiz S; Alexion Pharmaceuticals Inc, Boston, MA, USA.
Vallee M; Alexion Pharmaceuticals Inc, Boston, MA, USA.
Greenbaum LA; Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.

Pediatr Nephrol ; 36(4): 1033, 2021 Apr.

Article em En | MEDLINE | ID: mdl-33296010

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão